Record Q2 growth, but capex surge and Q3 softness cloud near-term
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Hit Q2 revenue/profit vs. delivered; margin guidance sustained; capex raised (not maintained); Q3 headwind disclosed upfront (credibility positive).
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Record Q2 (₹2,206 Cr, +33% YoY, NPM 19.6%) validates guidance and shows structural CDMO strength (86% growth). But ₹3K capex raise, flagged Q3 softness (Laurus Bio ramp-down), and unquantified peptide timeline (validations 12–18 months, revenue '28) create near-term FCF headwind. Long-term trajectory (CDMO 50% by FY30, ROCE 19%→25%) is credible but depends on execution.
₹2206.4 Cr
Revenue · +33.4% YoY₹436.2 Cr
Reported PAT · +124.3% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 total revenue ₹2,206 Cr, highest ever
METDelivered ₹2,206.4 Cr; YoY +33.4%, QoQ +8.9%
CDMO 86% growth in Q2 with sales ₹875 Cr
METH1 CDMO ₹1,710 Cr (77% growth YoY); 125 active programs delivering
Gross margin 63%, EBITDA margin 34.5% in Q2
METDelivered OPM 34%, gross margin~63%; margin expansion from Q1
PAT ₹441 Cr in Q2 vs ₹809 Cr in H1
METDelivered Q2 PAT ₹436.2 Cr; NPM 19.6%, consistent with call
Capex ₹3,000 Cr for FY27-'28 (raised from ₹2,000 Cr)
METH1 capex ₹864 Cr on track; raises prior guidance, aligns with expansion
Laurus Bio Q2 ₹29 Cr (down 16% YoY due to campaign phasing)
METAcknowledged Q3 softness; H1 ₹64 Cr vs prior ₹200 Cr illustrates tapering
Earnings quality
What changed since the last call
Capex guidance raised to ₹3,000 Cr
UpgradePrior FY27 guidance ₹2,000 Cr; now ₹3,000 Cr for FY27-'28 period; driven by peptide capacity, KRKA, Laurus Bio expansion
CDMO growth outpacing expectations
Upgrade86% growth in Q2 (₹875 Cr) vs prior implied mid-40% pace; 125 active programs showing commercial traction
Margin expansion confirmed despite capex
NeutralEBITDA 34.5% in Q2 vs 33.2% in H1; guidance 30%+ EBITDA maintained; operational leverage offsetting R&D spend
ROCE trajectory ahead of target
UpgradeNow 22.5% for H1 vs FY26 17.7%; on track toward 25% target (prior guidance 19%→25%)
Laurus Bio near-term softness flagged
DowngradeQ3 expected 'soft' due to validation and campaign phasing; H1 ₹64 Cr vs ₹200 Cr prior (down ~68% YoY)
The Q&A
Analysts pressed hard on peptide capacity, customer concentration, capex breakdown, and Laurus Bio trajectory. Management held firm on margin guidance, deflected on competitor-sensitive details (project specs, capex modality mix), and disclosed Q3 softness upfront. Tone: skeptical but not hostile; management credible where transparent.
Peptide commercialization timeline — Tushar, Motilal Oswal
AnsweredExpect commercial revenues around 2-year timeframe; facilities qualified for validation campaigns; high utilization expected once approved
CDMO growth drivers Q1 to Q2 — Sajal Kapoor, Antifragile Thinking
PartialOrganic growth; programs commercializing from development to late-stage; clinical programs moving through phases; no specific one-offs called out
CDMO sequential growth quality — Chirag Shah, White Pine
PartialMeaningful organic growth; no one-off large molecules; quality and technical capabilities adding customers; capabilities expanding
Peptide modality mix outlook — Sekhar Kadiyala, Family Office
AnsweredAll modalities will coexist; SPPS, LPPS, hybrid, fermentation each serve unique requirements; no single winner; ongoing expansion across all
EBITDA margin sustainability — Foram Parekh, BOB Capital
AnsweredEBITDA margin improvement from operational leverage; R&D cost rationalization underway; guiding 30%+ EBITDA floor
CDMO project portfolio concentration — Rahul Bharadwaj, Individual
DodgedCannot disclose granular project mix; ranges from USD 200K to USD 10M; difficult to quantify revenue impact per project
Peptide facility capex and asset turns — Dhawal, Jefferies
PartialReactor volume ~16K liters for SPPS synthesis; validation timelines 12-18 months; strategic not to disclose capex assumptions
Peptide backward integration and customer mix — Vivek Agrawal, Citigroup
DodgedCannot disclose specifics due to confidentiality; customers asking for capacity; expanding based on early clinical phase programs
KRKA JV timeline and contribution — Nayan Padsala, Individual
AnsweredValidation starting mid-2027; expect meaningful contributions by FY28-29 once validations complete and filings proceed
Peptide capex ballpark disclosure — Shrikant Akolkar, Nuvama
DodgedCannot disclose strategic reasons; customer feedback incorporated post-deliberation; no specific number given
Q2 margin sustainability forward — Krish Mehta, Enam Holdings
AnsweredCommitted to 60%+ gross margin and 30%+ EBITDA; guidance stands; margin profile sustainable given operational leverage
Peptide purification criticality — Alankar Garude, Kotak Institutional
AnsweredPurification and isolation equally important as synthesis; investing in downstream capabilities; building integrated value chain
CDMO customer concentration risk — Yasser Lakdawala, M3
PartialNo significant concentration; 120+ customers; well-diversified; strong pipeline visibility; no patent cliff or major destocking foreseen
Laurus Bio H1 decline and H2 outlook — Arindam Mukerjee, Individual
AnsweredExtra inventory as of Sept 30 for H3; utilized in coming quarter; capex investments ongoing; FCF healthy post-investments
Asset turns trajectory and capex efficiency — Tushar Manudhane, Motilal Oswal
AnsweredAverage asset turns 1.1x over 6 years; can move to 1.4x at peak; greenfield/brownfield capex will mature over time
Small molecule project pipeline and GLP-1 — Dhawal Khut, Jefferies
PartialMultiple projects at NDA stage; cannot disclose specifics; programs range in scale; visibility good for next 18-24 months
Guidance
CDMO to reach 50% of total revenue by FY30
MediumCurrent CDMO ~35-40% of revenue; implies 10-15% CAGR on CDMO base; 4-year horizon; no interim milestones disclosed
Affordable Medicines to maintain double-digit growth
HighH1 growth 13%; order book expanding; pricing stable; emerging market tailwinds
Laurus Bio revenue inflection from mid-2027 as validation completes
MediumPhase 1 fermentation facility operational by end FY27; commercial supplies expected in Q1 FY28; dependent on validation timeline
Gross margin 60%+ (currently 63%)
HighAchieved in H1; mix of CDMO growth and stable Affordable Medicines pricing support floor
EBITDA margin 30%+ (currently 34.5% in Q2)
HighOperational leverage and improved division/product mix expanding margins; R&D spend 4.3% of sales sustainable
FY27-'28 capex ₹3,000 Cr (raised from ₹2,000 Cr)
HighPrimary focus: peptide manufacturing scale-up, Laurus Bio fermentation (500K-liter facility), KRKA JV, API capacity expansion
Risks the call surfaced
Peptide validation execution
High12-18 month validation timelines for peptide synthesis; clinical programs dependent on regulatory approvals; delay in validation cascades revenue inflection
Capex intensity and FCF pressure
Medium₹3,000 Cr capex over FY27-'28 is aggressive; will strain FCF despite strong operating cash flow; ROI on peptide/Laurus Bio capex dependent on revenue inflection
Laurus Bio ramp-up execution
MediumLaurus Bio Q2 revenue ₹29 Cr (down 16% YoY); facility validation delays or yield issues will push revenue recovery to FY28+, reducing near-term growth
CDMO customer concentration
MediumManagement states 'no significant concentration' but provides no granular detail; 125 programs spread across 100+ customers, but revenue contribution per customer unknown; risk of destocking or customer consolidation
Raw material and supply chain volatility
LowSupply chain resilience maintained despite geopolitical headwinds; stable pricing achieved for ARV APIs; but commodity inflation or sourcing disruption could compress margins
Management
Score 7/10. Transparent on quarter results and guidance; disclosed Q3 softness upfront (positive). Evasive on commercially-sensitive details (customer concentration, project pipeline specifics, capex breakdown by modality). Disclosure quality mixed. Strong Q2 delivery (revenue ₹2,206 Cr, PAT ₹436 Cr) vs. guidance; margin guidance sustained (34.5% EBITDA); ROCE improving (17.7% FY26 → 22.5% H1). Capex raised to ₹3,000 Cr shows confidence but also replans prior guidance.
1 · Q3 FY27
Laurus Bio validation batch; facility qualification expected to resume revenue
2 · Q4 FY27 / Q1 FY28
Peptide manufacturing block commercial scale validation batches; first revenue generation timeline
3 · Mid-2027
KRKA formulation facility validation kick-off; JV contribution begins
Long-term trajectory (CDMO 50% by FY30, ROCE 19%→25%) is credible but depends on execution.
Informational and educational content only. Not investment advice.